A new treatment target includes mucosal healing as well as clinical remission
In the late 1990s, controlled trials confirmed the efficacy of tumour necrosis factor-alpha (TNF-α) antibodies in treating active Crohn’s disease, signalling a major breakthrough in treatment. TNF-α monoclonal antibody therapy has since been shown to lead to significant improvements in quality of life and symptom control and a decrease in the need for surgery and prolonged hospitalisation for patients with Crohn’s disease.1 The development of such an effective form of treatment has led not only to a change in the paradigm for treating Crohn’s disease, but also to an increasing awareness of its limitations.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.